Biocon, Mylan launch first insulin glargine biosimilar, Semglee in Australia
Biocon Ltd and Mylan N.V. announced the launch of Semglee (insulin glargine solution for injection 100 IU/mL in a 3mL pre-filled pen),... Read More
USFDA approval of Rituxan, in combination with glucocorticoids, for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in paediatric patients 2 years of age and older
Roche announced that the US Food and Drug Administration (FDA) has approved Rituxan (rituximab), in combination with glucocorticoids, for the treatment of... Read More
Case Study: USFDA approval of AbbVie’s RINVOQ (upadacitinib)
U.S. Food and Drug Administration (FDA) has approved RINVOQ™ (upadacitinib), a 15 mg, once-daily oral Janus kinase (JAK) inhibitor, for the treatment... Read More
List of USFDA approved Biosimilar [till date]
Click here to view the list.
US FDA approves Pfizer’s Biosimilar Zirabev
Pfizer Inc announced the US FDA has approved Zirabev (bevacizumab-bvzr), a biosimilar to Avastin (bevacizumab), for the treatment of five types of... Read More
Top 10 Generic Company Globally in 2018 (by revenue)
Here you can preview top 10 global generic companies by revenue. Data is presented in USD million. Click here to view the... Read More
Take a self competency test in authorized generics
In the U.S., prescription drugs approved by the federal Food and Drug Administration (FDA) are granted a specified period of market exclusivity,... Read More
Health Canada approves Biocon and Mylan’s trastuzumab biosimilar ‘Ogivri’ for HER2-positive cancers
Biocon and Mylan have received the clearance from Health Canada for the latter’s biosimilar Herceptin: trastuzumab co-developed under the brand name Ogivri... Read More
Case Study – A close look into Eli Lilly’s pricing strategy for Insulin Lispro injection in US market
Eli Lilly and Company’s has announced that its Insulin Lispro Injection is now available for order in pharmacies for people who use... Read More
Sandoz licensing agreement with EirGenix to commercialize trastuzumab biosimilar
Posted on02 May 2019
TagsBiosimilar, biosimilar deals, biosimilar of sandoz, drug licensing, EirGenix, sandoz, trastuzumab
Comments0
Sandoz, a Novartis division and a global leader in biosimilars, has entered into an agreement to commercialize a proposed trastuzumab biosimilar. This... Read More